September 12, 2022

By EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7010

Re: Anixa Biosciences, Inc.

Registration Statement on Form S-3 (File No. 333-267369)

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form S-3 (File No. 333-267369) filed by Anixa Biosciences, Inc. on September 9, 2022 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933 (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated onto the cover page of the Registration Statement.

“The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.”

Sincerely,

/s/ Michael J. Catelani

Michael J. Catelani

President, Chief Financial Officer and Chief Operating Officer